GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cepheid (NAS:CPHD) » Definitions » Days Sales Outstanding

Cepheid (Cepheid) Days Sales Outstanding : 41.67 (As of Sep. 2016)


View and export this data going back to 2000. Start your Free Trial

What is Cepheid Days Sales Outstanding?

Cepheid's average Accounts Receivable for the three months ended in Sep. 2016 was $72.4 Mil. Cepheid's Revenue for the three months ended in Sep. 2016 was $158.5 Mil. Hence, Cepheid's Days Sales Outstanding for the three months ended in Sep. 2016 was 41.67.

The historical rank and industry rank for Cepheid's Days Sales Outstanding or its related term are showing as below:

CPHD's Days Sales Outstanding is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 69.24
* Ranked among companies with meaningful Days Sales Outstanding only.

Cepheid's Days Sales Outstanding declined from Sep. 2015 (49.84) to Sep. 2016 (41.67).


Cepheid Days Sales Outstanding Historical Data

The historical data trend for Cepheid's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cepheid Days Sales Outstanding Chart

Cepheid Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.67 43.74 43.75 46.97 45.87

Cepheid Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.84 39.40 43.86 42.33 41.67

Competitive Comparison of Cepheid's Days Sales Outstanding

For the Diagnostics & Research subindustry, Cepheid's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cepheid's Days Sales Outstanding Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cepheid's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Cepheid's Days Sales Outstanding falls into.



Cepheid Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Cepheid's Days Sales Outstanding for the fiscal year that ended in Dec. 2015 is calculated as

Days Sales Outstanding (A: Dec. 2015 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2014 ) + Accounts Receivable (A: Dec. 2015 )) / count ) / Revenue (A: Dec. 2015 )*Days in Period
=( (68.809 + 66.55) / 2 ) / 538.576*365
=67.6795 / 538.576*365
=45.87

Cepheid's Days Sales Outstanding for the quarter that ended in Sep. 2016 is calculated as:

Days Sales Outstanding (Q: Sep. 2016 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2016 ) + Accounts Receivable (A: Sep. 2016 )) / count ) / Revenue (A: Sep. 2016 )*Days in Period
=( (62.828 + 81.91) / 2 ) / 158.488*365 / 4
=72.369 / 158.488*365 / 4
=41.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cepheid  (NAS:CPHD) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Cepheid Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Cepheid's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Cepheid (Cepheid) Business Description

Traded in Other Exchanges
N/A
Address
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.
Executives
Thomas D Brown director 28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK, LAKE MARY FL 32746-6232
Hollings Renton director
John L Bishop director, officer: Chairman of the Board and CEO
Marc Haugen officer: EVP, Global Ops & Engineering C/O CEPHEID, 904 CARIBBEAN DRIVE, SUNNYVALE CA 94089
Ilan Daskal officer: EVP, Chief Financial Officer 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew Miller officer: EVP, CFO 111 MCINNIS PARKWAY, SAN RAFAEL CA 94903
Jim Post officer: EVP, NA Commercial Operations 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453

Cepheid (Cepheid) Headlines

From GuruFocus

Baron Funds Comments on Cepheid

By Holly LaFon Holly LaFon 02-08-2016

Mario Gabelli Comments on Cepheid

By Holly LaFon Holly LaFon 01-31-2017

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 10,000 Shares

By GuruFocus Research GuruFocus Editor 12-10-2010

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 08-04-2010

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares

By GuruFocus Research GuruFocus Editor 02-08-2011

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2009

Columbia Wanger Sold 2 Stakes in September

By David Goodloe David Goodloe 10-07-2016

CEPHEID Reports Operating Results (10-K/A)

By gurufocus 10qk 10-01-2009

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares

By GuruFocus Research GuruFocus Editor 02-15-2011